1. Home
  2. OBDE vs ZLAB Comparison

OBDE vs ZLAB Comparison

Compare OBDE & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBDE
  • ZLAB
  • Stock Information
  • Founded
  • OBDE 2020
  • ZLAB 2013
  • Country
  • OBDE United States
  • ZLAB China
  • Employees
  • OBDE N/A
  • ZLAB N/A
  • Industry
  • OBDE
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • OBDE
  • ZLAB Health Care
  • Exchange
  • OBDE NYSE
  • ZLAB Nasdaq
  • Market Cap
  • OBDE 1.8B
  • ZLAB 1.8B
  • IPO Year
  • OBDE N/A
  • ZLAB 2017
  • Fundamental
  • Price
  • OBDE $14.55
  • ZLAB $31.24
  • Analyst Decision
  • OBDE Buy
  • ZLAB Strong Buy
  • Analyst Count
  • OBDE 1
  • ZLAB 4
  • Target Price
  • OBDE $16.00
  • ZLAB $52.50
  • AVG Volume (30 Days)
  • OBDE 180.0K
  • ZLAB 976.3K
  • Earning Date
  • OBDE 11-06-2024
  • ZLAB 11-12-2024
  • Dividend Yield
  • OBDE 4.03%
  • ZLAB N/A
  • EPS Growth
  • OBDE N/A
  • ZLAB N/A
  • EPS
  • OBDE N/A
  • ZLAB N/A
  • Revenue
  • OBDE N/A
  • ZLAB $322,711,000.00
  • Revenue This Year
  • OBDE N/A
  • ZLAB $48.34
  • Revenue Next Year
  • OBDE N/A
  • ZLAB $47.12
  • P/E Ratio
  • OBDE N/A
  • ZLAB N/A
  • Revenue Growth
  • OBDE N/A
  • ZLAB 28.16
  • 52 Week Low
  • OBDE $13.60
  • ZLAB $13.48
  • 52 Week High
  • OBDE $16.80
  • ZLAB $36.60
  • Technical
  • Relative Strength Index (RSI)
  • OBDE 55.89
  • ZLAB 70.41
  • Support Level
  • OBDE $14.16
  • ZLAB $31.52
  • Resistance Level
  • OBDE $14.65
  • ZLAB $36.60
  • Average True Range (ATR)
  • OBDE 0.20
  • ZLAB 1.36
  • MACD
  • OBDE 0.01
  • ZLAB 0.34
  • Stochastic Oscillator
  • OBDE 80.33
  • ZLAB 58.60

About OBDE BLUE OWL CAPITAL CORP III

Blue Owl Capital Corp III is focused on originating and making loans to, and debt and equity investments in middle-market companies based predominantly in the United States. Its objective is to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns. The company invests in senior secured or unsecured loans, subordinated loans or mezzanine loans and, to a lesser extent, equity and equity-related securities including warrants, preferred stock and similar forms of senior equity, which may or may not be convertible into a portfolio company's common equity.

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Share on Social Networks: